Statistics for Keros Therapeutics (id:6457 KROS)

Valuation metrics

Market cap

2.63B

Enterprise value

2.12B

Trailing P/E (ttm)

-10.75

Forward P/E

-11.38

PEG ratio

-11.38

Price/Sales (ttm)

4.04K

Price/Book (mrq)

4.78

Enterprise Value/Revenue

3.25K

Enterprise Value/EBITDA

-10.43

Overview

Shares outstanding

40.51M

Float

35.37M

Shares short

2.72M

% Held by insiders

0.05%

% Held by institutions

0.93%

Average volume (10 days)

438.69K

Average volume (90 days)

Price summary

52-Week low

27.31

52-Week high

73.00

52-Week change

44.98%

Beta

1.24

50-Day moving average

58.65

200-Day moving average

55.33

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-15,117.78%

Operational effectiveness

Return on assets

-28.16%

Return on equity

-43.82%

Income statement

Revenue (ttm)

0.02

Revenue per share (ttm)

0.02

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-202,890,000.00

Net income to common (ttm)

-181,570,000.00

Diluted EPS (ttm)

-5.22

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

530.68M

Total cash per share (mrq)

13.10

Total debt (mrq)

19.29M

Total Debt/Equity (mrq)

3.62

Current ratio (mrq)

1.90K%

Book value per share (mrq)

13.57

Cash flow

Cash flow statement

-140,320,000.00

Levered free cash flow (LFCF)

-89,324,248.00